The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma
-
- Nagaya Naoya
- Department of Urology, Juntendo University Graduate School of Medicine, Japan
-
- Kanayama Mayuko
- Department of Urology, Juntendo University Graduate School of Medicine, Japan
-
- Nagata Masayoshi
- Department of Urology, Juntendo University Graduate School of Medicine, Japan
-
- Horie Shigeo
- Department of Urology, Juntendo University Graduate School of Medicine, Japan
Search this article
Description
<p>Circulating tumor cells (CTCs) are a promising biomarker for several cancers. We streamlined the experimental procedure of CTC immunofluorescent staining. We encountered a 72-year-old woman with metastatic right renal cell carcinoma (RCC) (clinical stage: T4N0M1), whose CTC number rapidly increased after the administration of sunitinib and then gradually decreased. The change in the CTC number appeared to coincide with laboratory data and hypertension, suggesting that a CTC analysis may be useful for promptly monitoring the treatment response. Our data provided the first evidence of an association between the CTC numbers and the treatment response in a metastatic RCC patient. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 57 (18), 2695-2700, 2018-09-15
The Japanese Society of Internal Medicine
